Modifi Bio
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Modifi Bio (Modifi Biosciences) was a preclinical-stage biotechnology company founded in 2021 as a Yale University spinout by Ranjit Bindra and Seth Herzon, based in New Haven, Connecticut. It created a new class of small molecules, described as 'chameleon-like', designed to be delivered orally and to selectively kill cancer cells via direct DNA modification — particularly cancer cells lacking the DNA repair protein MGMT, including chemotherapy-resistant glioblastoma — while sparing normal tissue. Its lead candidate MOD-246 showed robust anti-tumor activity in lab studies. In October 2024, Merck acquired Modifi Bio for $30 million upfront, with total deal value potentially reaching $1.3 billion in milestone payments.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Ranjit Bindra and Seth Herzon found Modifi Bio as a Yale University spinout in New Haven, Connecticut, to develop DNA-modifying molecules against cancer.
- Seed funding
Modifi Bio closes a $4.3 million seed round in October 2023; the company had raised $10.7 million in seed funding overall.
- Acquisition
Merck acquires Modifi Bio in October 2024 for $30 million upfront, with total deal value potentially reaching $1.3 billion in milestone payments.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.